For the quarter ending 2025-09-30, KYTX made $40,776K in revenue. -$36,738K in net income. Net profit margin of -90.10%.
| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 30,457 | 35,816 | ||
| General and administrative | 8,270 | 8,594 | ||
| Total operating expenses | 38,727 | 44,410 | ||
| Loss from operations | -38,727 | -44,410 | ||
| Interest income | 2,000 | 2,364 | ||
| Interest expense | 7 | 14 | ||
| Other expenses, net | -53 | -21 | ||
| Total other income, net | 1,940 | 2,329 | ||
| Net loss | -36,787 | -42,081 | ||
| Unrealized gain (loss) on marketable securities, net | 49 | -19 | ||
| Total other comprehensive gain (loss) | 49 | -19 | ||
| Net loss and other comprehensive loss | -36,738 | -42,100 | ||
| Earnings per share, basic, total | -0.85 | -0.97 | ||
| Earnings per share, diluted, total | -0.85 | -0.97 | ||
| Weighted average number of shares outstanding, basic, total | 43,415,367 | 43,225,365 | ||
| Weighted average number of shares outstanding, diluted, total | 43,415,367 | 43,225,365 | ||
Kyverna Therapeutics, Inc. (KYTX)
Kyverna Therapeutics, Inc. (KYTX)